×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is ...
Yahoo Finance
Key Insights BioCardia to hold its Annual General Meeting on 20th of May Salary of US$515.5k is part of CEO Peter...
1 week ago
BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important ...
Diagnostic and Interventional Cardiology
May 2, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
3 weeks ago
BioCardia Reports Positive Interim Results From Phase III CardiAMP Cell Therapy Heart Failure Trial, With Compelling ...
HMP Global Learning Network
These positive results for CardiAMP cell therapy are very encouraging, especially for patients with elevated NTproBNP,” said trial...
2 months ago
Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable
Simply Wall Street
Key Insights BioCardia to hold its Annual General Meeting on 20th of May CEO Peter Altman's total compensation includes...
1 week ago
BioCardia Reveals Promising CardiAMP Trial Results in Webcast - TipRanks.com
Tipranks
BioCardia Inc (BCDA) has shared an announcement. BioCardia, Inc. has announced the results of a significant phase of their CardiAMP® Cell Therapy trial,...
3 weeks ago
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
GlobeNewswire
SUNNYVALE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics...
2 months ago
BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript
Yahoo Finance
BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript March 27, 2024 BioCardia, Inc. beats earnings expectations.
1 month ago
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic ...
Diagnostic and Interventional Cardiology
November 17, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
6 months ago
BioCardia stock jumps premarket as FDA approves heart failure trial (NASDAQ:BCDA)
Seeking Alpha
BioCardia (NASDAQ:BCDA) shares jumped over +105% premarket on Tuesday after the biotech firm received FDA approval for the Phase 3 clinical...
6 months ago
Earnings call: BioCardia optimistic amid clinical trial progress and Japan strategy
Investing.com South Africa
BioCardia, Inc. (NASDAQ: BCDA ) has reported a mixed financial performance in Q1 2024, alongside promising clinical trial results for its...
6 days ago